Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Has Opportunity To Lead On Ophthalmic Biosimilars

Cardinal Health’s Sonia Oskouei Expands On Findings Of 2022 Biosimilars Report

Executive Summary

With key milestones on the horizon for US biosimilars in 2022 and 2023, Cardinal Health’s vice president of biosimilars, Sonia Oskouei, explains how the industry can best position itself to take advantage of these upcoming opportunities – including potentially a global leadership role in ophthalmology – in an exclusive interview with Generics Bulletin.

You may also be interested in...



Amgen Urges Adoption Of Balanced Policies For Biosimilars

A balanced policy environment that can support biosimilar competition is needed to allow the drugs to flourish in the US, says Amgen’s executive director of marketing and global biosimilars commercial lead Chad Pettit.

Amgen Calls For Balance To Support Biosimilars

A balanced policy environment that supports competition is needed to allow biosimilars to flourish in the US, according to Amgen, along with strong and transparent IP processes to underpin continuing innovation in the biologics space. Chad Pettit, the firm’s executive director of marketing and global biosimilars commercial lead, talks to Generics Bulletin about the firm’s “unique perspective” on biosimilars.

Intas And Axantia Ink Middle East Ranibizumab Distribution Deal

Intas has secured a distributor for its ranibizumab biosimilar throughout select countries in the Middle East, while Phase III trials continue ahead of anticipated US approval.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151676

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel